The hybrid operating room at the Brigham and Women’s Hospital Heart & Vascular Center now features the state-of-art ARTIS Pheno angiography system. As of March 2018, patients who require hybrid cardiovascular interventions combining intravascular and open surgical procedures are reaping the rewards of this cutting-edge technology.
Advanced heart failure patients who received the HeartMate 3 left ventricular assist device (LVAD) in the MOMEMTUM 3 trial had fewer strokes and re-operations for pump malfunction compared with its predecessor, the HeartMate 2. The findings from Brigham and Women’s Hospital were published in the New England Journal of Medicine earlier this year and simultaneously presented at the 2018 American College of Cardiology Scientific Sessions.
The history of surgery for valvular heart disease at Brigham and Women’s Hospital (BWH) dates to May 1923 when Elliott Carr Cutler, MD, performed the first ever valve operation in the world. Since then, BWH has been at the forefront of the clinical practice and innovation in the management of valve disease. Read More
A new analysis seeks to answer the question of which patients are likely to gain the greatest cardiovascular benefit when treated with the anti-inflammatory agent canakinumab. At the 2017 American Heart Association Scientific Sessions, Paul M. Ridker, MD, director of the Center for Cardiovascular Disease Prevention at Brigham and Women’s Hospital, presented a pre-specified analysis on CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) that identifies a simple, clinical method to define patient groups most likely to benefit from long-term canakinumab treatment. The results of this analysis, published simultaneously in The Lancet, could have a major impact not only on patient selection and cost-effectiveness of canakinumab, but also on the future development of anti-inflammatory agents for cardiovascular disease. Read More
Programs at Brigham and Women’s Hospital can assist you in caring for your patients with complex disorders, including evaluation and treatment for a range of abnormal heart rhythms.
Cardiac electrophysiologist and arrhythmia specialist Paul C. Zei, MD, PhD, joined the Heart Rhythm Disorders Program at Brigham and Women’s Hospital (BWH) as director of the Comprehensive Atrial Fibrillation Program (CAFP) with the goal of establishing it as one of the leading programs in the world for managing patients with atrial fibrillation (AF). Read More
Researchers have been able to generate induced pluripotent stem cells from patients with Hutchinson-Gilford progeria syndrome (HGPS) to better understand the mechanisms of aging and look for new treatments. Read More
Cardiac surgeons at Brigham and Women’s Hospital performed an innovative endovascular procedure to treat a ruptured ascending aortic pseudoaneurysm. Read More